Fortis Healthcare Limited’s board has recommended the re-appointment of Dr. Ashutosh Raghuvanshi as Managing Director and Chief Executive Officer for a further period of two years, effective from March 19, 2027. The decision, taken during a board meeting on July 8, 2026, is subject to the approval of shareholders. Dr. Raghuvanshi currently serves as the Managing Director & Chief Executive Officer of the company, and his current term is set to expire on March 18, 2027.

The board cited Dr. Raghuvanshi’s expertise and his role in steering the growth of the company as reasons for the recommendation. The re-appointment proposal includes a disclosure confirming that he is not debarred from accessing the capital markets or restrained from holding the position of director by SEBI or any other authority. The detailed disclosures regarding the appointment are enclosed as per the SEBI Master Circular dated January 30, 2026.

Dr. Ashutosh Raghuvanshi, aged about 64 years, holds an MBBS and an M.S. in General Surgery from Mahatma Gandhi Institute of Medical Sciences, Wardha, and an M.Ch. in Cardiac Surgery from Bombay Hospital Institute of Medical Sciences. He brings over 38 years of experience in the healthcare sector to the role. Prior to joining Fortis Healthcare , he spent over 18 years with Narayana Health, where he held leadership positions including Vice Chairman, Managing Director, and Group Chief Executive Officer.

Key Details of Re-appointment

Dr. Raghuvanshi is not related to any of the other directors of the company. He has received numerous national and international awards for his contributions to the industry and has been closely engaged with industry bodies such as CII, FICCI, and NATHEALTH, having served as President of NATHEALTH from 2023 to 2024. The board meeting commenced at 01:00 PM IST and concluded at 02:30 PM IST.

Northern TK Venture Pte. Ltd. disclosed its shareholding in Fortis Healthcare for the financial year ended 31 March 2026, confirming the ownership of 235,295,895 equity shares. The declaration, submitted to the stock exchanges, stated that no shares were encumbered directly or indirectly during FY26. This disclosure is mandated under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011.

The filing addressed the Corporate Communications Department of the National Stock Exchange of India Ltd. and the Department of Corporate Services of BSE Ltd. It confirmed that the shareholding position remained unchanged regarding encumbrances throughout the specified financial year. The document was signed by Agarwal Aanchal, Director of Northern TK Venture Pte. Ltd., from Malaysia on 2 April 2026.

Shareholding Details

The disclosure provides specific data regarding the entity's position in Fortis Healthcare Limited for the period ending 31 March 2026.

Regulatory Compliance

The submission was made in compliance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011. This regulation requires entities holding substantial shares to declare their holdings and confirm whether any shares have been encumbered during the financial year. A copy of the disclosure was also sent to the Company Secretary & Compliance Officer and the Audit Committee of Fortis Healthcare Limited.